Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT03296852Phase 1Completed
Phase 1, open-label, single-arm trial, sponsored by University of California, Los Angeles. Primary endpoint: Blood brain barrier impairment by extravasation of Gadolinium into the brain tissue at 5 hours. Started Apr 2018; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT03296852.